Objective: To assess the performance of 18 F-FDG PET/CT in the malignancy diagnosis of adrenal masses in noncancer patients.
(Tumor SUV max :Liver SUV max ) the ratio for malignancy was .1.5 with sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 86.7%, 86.1%, 56.5%, 96.9%, and 86.2%, respectively. T he adrenal glands can be affected by a variety of pathologic processes (e.g., primary and secondary neoplasms, hyperplasia, and miscellaneous disorders). Tumors that originate from the adrenal cortex (collectively named adrenocortical tumors) can either be benign or malignant, secreting or not secreting. Adrenomedullary tumors include pheochromocytoma (PHEO; chromaffin-cell origin) and various neoplasms arising from autonomic ganglion cells or their precursors.
Conclusions
Most of the adrenocortical tumors are incidentally discovered on an imaging study performed for other indications. These lesions are usually called incidentalomas, but this term reflects their mode of discovery rather than their nature. They are found in~4% of abdominal computed tomography (CT) scans and are benign in nature.
The evaluation of adrenal masses requires, firstly, a complete clinical evaluation (a thorough medical history and physical examination) in addition to relevant endocrine panels. Negative plasma/urine metanephrines largely rule out the diagnosis of PHEO. The presence of steroid hypersecretion (adrenocorticotropic hormone-independent Cushing syndrome, primary aldosteronism, and/or hyperandrogenism) enables the diagnosis of an adrenocortical tumor, which when associated with multiple secretion patterns and/or rapid clinical progression is highly suspicious for malignancy. A negative previous history of cancer and an absence of additional tumor sites on CT are strong arguments against the possibility of adrenal metastasis.
In a second step, a combination of unenhanced density and sufficient tumor size on CT can reliably characterize incidentally detected adrenal masses, unenhanced density ,10 Hounsfield units (HU), and size ,4 cm being associated with a benign course. Tumor size represents a useful predictor of malignancy, with posttest probabilities of 10%, 19%, and 47% for cancer in adrenocortical tumors $4 cm, $6 cm, and $8 cm, respectively (1, 2) .
Lastly, in large tumors $4 cm and/or those with an unenhanced density $10 HU, adrenal washout CT and/ or adrenal magnetic resonance imaging with chemical shift play a central role in the characterization of adrenal masses. Adrenocortical adenomas (ACAs) typically exhibit an absolute enhancement washout of $60% and/ or relative enhancement washout of $40% on CT examination, or demonstrate signal loss in opposed-phased magnetic resonance imaging. If an adrenal adenoma cannot be predicted based upon these criteria, a diagnosis is required by either histopathology or by short-term imaging evaluation. Adrenal biopsy should only be performed if the results are likely to alter the management of the patient and after excluding a PHEO, due to the risk of catecholamineinduced (released by mass biopsy and/or anesthetics) hypertensive crisis and tachyarrhythmia (3) . Surgery performed by experienced hands is the only way to cure adrenocortical carcinoma (ACC) and should not be delayed because further tumor growth may compromise the possibility of tumor resection. Therefore, despite the absence of hormonal hypersecretion, some tumors may require surgical resection such as large, rapidly growing, or suspicious indeterminate tumors on CT. This diagnostic uncertainty may contribute to excessive resection of benign tumors with subsequent potential surgical morbidity.
In recent years, 18 F-fluorodeoxyglucose positron emission tomography/CT ( 18 F-FDG PET/CT) has gained an increasing role in oncology, including the diagnosis of adrenal masses in patients with cancer or patients with a previous history of cancer (4) (5) (6) . Few studies have shown that 18 F-FDG PET/CT could also provide information regarding the nature of indeterminate adrenal masses on CT. However, its role in the evaluation of adrenal masses in noncancer patients is still debated due to a lack of robust studies (5, 6) .
The primary objective of this prospective, multicenter study was to assess the diagnostic value of 18 F-FDG PET/ CT in the diagnosis of malignancy among large ($40 mm) and/or indeterminate adrenal masses in noncancer patients.
Material and Methods
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Study design
The current study was a prospective, multicenter study (eight French institutions) that aimed to evaluate the role of 18 F-FDG PET/CT in the characterization of indeterminate and/or large adrenal masses found incidentally by CT, which are usually referred to endocrine surgeons for potential adrenalectomy. All patients who fulfilled the eligibility criteria were evaluated by 18 F-FDG PET/CT. Patients were evaluated during five study visits: enrollment, eligibility (visit 0), 18 F-FDG PET/CT (visit 1), postoperative period for operated patients (visit 2), as well as 6-month (visit 3) and 12-month (visit 4) follow-up after initial 18 F-FDG PET/CT. According to the study design, the imaging follow-up was required only for patients who did not have adrenal surgery.
Eligibility criteria
The inclusion criteria were (all criteria) as follows: The study was approved by the local ethics committee (Comité de Protection des Personnes Sud-Méditerranée I: 25 October 2010). The study had been registered with ClinicalTrials.gov (identifier: NCT01284829). Informed consent was obtained from all individual participants included in the study.
F-FDG PET/CT
Acquisition 18 F-FDG PET/CT was performed in each nuclear medicine department according to usual practice (arms above head during acquisition). Different PET/CT cameras were used: GE/ Discovery ST in Marseille, GE G71016S in Bordeaux, GE Discovery HD RX 16 in Lille, Siemens/Biograph 6 True Point/ True V in Nancy, Siemens/Biograph mCT 40 and Biograph mCT 64 in Nantes, and GE/Discovery 710 in Lyon (Supplemental Table 1 ). All patients fasted for 6 hours prior to scanning. 
Gold standard
Histology was considered the gold standard for the diagnosis of benign, malignant, or indeterminate lesions. For adrenocortical tumors, the distinction between benign and malignant tumors was based on the Weiss score, ACCs being defined by a Weiss score $3. For oncocytomas, tumors were classified according to the Bisceglia scoring system. The existence of at least one major criterion defines a malignant oncocytoma, with one to four minor criteria indicating uncertain malignant potential (borderline). There was no central pathology review, but the scoring was performed on site by expert pathologists.
In other cases, the nature of the lesion was based on the 12-month imaging follow-up. Benignity was assumed when the mass remained stable or had minimal increase in size (,15%) of the tumor diameter on the 12-month (62 months) follow-up CT. Tumors diagnosed with uncertain malignant potential on final pathology were considered as benign.
Statistical analysis
The sample size calculation was performed from hypothesis on AUC for T mx :M mx . To estimate an AUC of 0.90 (based on unpublished data from D.T.) with a precision of 10%, considering an expected proportion of malignant tumors of 15%, the sample size required was 118.
Due to the deceleration of the inclusion rate, as well as end of funding, enrollment was stopped after a 4-year inclusion period for a total of 95 patients. Because previous published studies lacked robustness, it was of major importance to publish data in accordance with the investigators. With a proportion of malignant tumors of 17%, a sample size of 95 individuals allows to estimate an AUC of 0.92 with a precision of 10%.
Statistical analysis was performed by using IBM SPSS Statistics version 20 (IBM SPSS, Inc., Chicago, IL). Continuous variables are expressed as mean 6 standard deviation (SD) or medians with range (minimum, maximum), and categorical variables are reported as count and percentages. All the tests were two-sided. Statistical significance was defined as P , 0.05. 
·
The optimal threshold to better discriminate between benign and malignant disease was calculated. Sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV), and accuracy were provided with their 95% confidence intervals. Sensitivity analyses were performed using the same procedure for tumors with uncertain diagnosis classified as malignant disease.
Comparisons of the sensitivities and specificities of VA and T mx :L mx in the different groups were performed according to Hawass (7) . Two other populations were defined (sensitivity analysis): the subgroup of masses with unenhanced CT attenuation density $10; and the subgroup of adrenocortical tumors. The same procedure was performed on these two subgroups and results are provided in Supplemental Table 2 .
The interobserver variability (IOV) was calculated for both uptake ratios and expressed as intraclass correlation coefficients. Results were interpreted according to Cicchetti (8) guidelines.
Results
Patients
Of the total 95 enrolled patients with adrenal masses, eight patients were excluded from the analysis. In seven cases, imaging findings were not analyzed due to the presence of elevated metanephrines in six cases (with histological confirmation of PHEO) or because of the presence of multiple lesions on CT in one case (lymphoma). In the latter case, the patient refused to be evaluated by PET imaging. The study population consisted of 87 patients (53 women, 34 men; mean age of 55 years): 56 had masses $40 mm (13/56 had an unenhanced density ,10 HU) and 31 had indeterminate masses on washout CT with maximal diameter ,40 mm. No patient with bilateral large and/or indeterminate adrenal masses was enrolled in the study.
Management
Management and therapeutic decisions were made with the knowledge of the PET/CT findings. Sixty-three patients (72%) underwent adrenalectomy, including total adrenalectomy (with or without clearance of the surrounding fatty tissue) for 60 cases and adrenalectomy with multivisceral resection in three cases. Resection of adjacent organs was performed for primary large adrenocortical tumors: one 90-mm left oncocytoma of uncertain malignant potential (bloc resection of tumor with pancreas tail, spleen, kidney, and diaphragm), one 100-mm right ACC (bloc resection of tumor with liver and kidney resection), and one 38-mm left ACC (bloc resection of tumor with an accompanying portion of the diaphragm).
Final diagnosis
Following PET imaging, and according to the gold standard, 72 masses were classified as benign and 15 as malignant. Histology was obtained in 64 patients (following surgery in 63 cases, biopsy in one case) and identified 15 malignant tumors (11 ACCs, one metastasis from lung carcinoma, two leiomyosarcomas, one liposarcoma); 47 benign tumors (34 ACAs, one nodular hyperplasia, two hematomas, one ganglioneuroma, two PHEOs [normal 24-hour urinary metanephrines], one lymphangioma, one schwannoma, one myelolipoma, two oncocytomas, two cysts), and two oncocytomas with uncertain malignant potential based on Bisceglia scoring. For analysis, all oncocytomas were classified as benign tumors. The adenoma Weiss scores were distributed as follows: score 0 = 21, score 1 = 7, and score 2 = 6. In these patients, no further adrenal imaging studies were performed, but patients having adenomas with Weiss scores of 1 and 2 were still alive after a median follow-up of 4.5 years (mean 6 SD, 4.09 6 1.02).
The remaining 23 cases remained stable on follow-up imaging studies for 12 months and were considered as benign lesions. Among these 23 adrenal masses without pathological confirmation, 14 had a maximal diameter ,40 mm (mean 6 SD: 25.2 6 7. 8 mm, median: 26 mm) and were included in the study based on abnormal washout CT values. The remaining nine cases had a maximal diameter $40 mm and were indeterminate on adrenal CT in six cases.
Among the subgroup of masses with unenhanced densities $10 HU (n = 74), 59 were classified as benign and 15 as malignant. Among the subgroup of adrenocortical tumors (n = 45), 34 were classified as benign and 11 as malignant.
Imaging findings
Compared with benign lesions, malignant lesions were larger in size, had a higher SD, lower washout values, and higher 18 F-FDG uptake values. These results were observed in the entire population (N = 87; Table 1 ), in the group of masses with unenhanced density $10 HU (N = 74), as well as in the group of adrenocortical tumors (Supplemental Table 3 ). None of the masses with unenhanced densities ,10 HU were malignant.
18 F-FDG uptake was not different between secreting and nonsecreting adrenocortical tumors (P = 0.670). No metastasis was observed on 18 F-FDG PET/CT. In the case with adrenal metastasis, the primary lung cancer was detected by PET imaging.
The threshold values of T mx , T mx :L mx , and T mx :L me obtained from ROC curves were .4.1, .1.5 (Fig. 1) , and 2.8, respectively, for differentiating benign from malignant lesions in the entire population (N = 87) (Tables 2  and 3 ) and in the group of masses with unenhanced densities $10 HU (n = 74; Supplemental Table 2 ). This finding did not differ when the two oncocytomas with uncertain malignant potential were classified as malignant tumors. Two malignant tumors had T mx :L mx uptake ratios ,1.5 and corresponded to a liposarcoma (ratio = 0.8) and an ACC (ratio = 1.4). The missed ACC (T mx :L mx = 1.4) on the basis of PET was removed via laparoscopic radical adrenalectomy and had the following characteristics: 48-mm tumor size, Weiss score of 6, no extraadrenal extension, absolute washout = 30%, and relative washout of 15% on adrenal CT. The four oncocytomas had ratios .2, (2.0; 4.0; 4.5; 13.6; Table 2 ). An ACC with an important oncocytic component also exhibited a marked 18 F-FDG uptake (T mx :L mx of 17.7).
The threshold values of T mx , T mx :L mx , and T mx :L me for distinguishing ACA from ACC were .3.4; 1.6 and .1.9 (34 ACAs versus 11 ACC; Supplemental Table 2 ). The performance of VA and PET quantitative parameters are detailed in Table 3 and Supplemental Table 2 . T mx :L mx had a higher specificity than VA in the three subgroups of adrenal masses. Although VA and uptake ratios had similar sensitivities, the ratios provided a better specificity.
In accordance with the Cicchetti (8) 
Discussion
This prospective, multicenter study evaluates the role of 18 F-FDG PET/CT in the characterization of indeterminate and/or large adrenal masses in nononcologic patients. European experts have recently stated the need of such studies to determine the most suitable imaging strategy in patients with equivocal findings at initial CT scanning (9) . The principal conclusions that can be drawn from this study include the following: firstly, 18 F-FDG PET/CT further characterizes indeterminate and/or large adrenal masses with an excellent NPV; secondly, a T mx :L mx uptake ratio ,1.5 represents the optimal cutoff values on the ROC curve, but physicians should be aware that ACC and liposarcomas that may mimic adrenal tumors may exhibit lower uptake values; and finally, oncocytomas (benign and malignant) exhibit highly elevated uptake 18 F-FDG values. Analysis of the literature is hampered by the frequent mixing of oncologic and nononcologic patients, suboptimal methodological study designs, and reporting of test accuracies, leading to a lack of robustness in metaanalyses (5, 6). Beyond major bias, few studies have provided important preliminary results in noncancer patients that merit discussion. SUV is commonly used for describing adrenal tumor 18 F-FDG uptake. Although calculation of SUV is hampered by many simplifications and approximations, it remains a simple quantitative parameter for in vivo assessment of tumor metabolism. Tumor SUV max , which is less affected by the partial volume effect, is the most frequently reported PET parameter and is often normalized by liver SUV max (also called SUV max tumor:liver uptake ratio; T mx :L mx ). Tessonnier et al. (10) reported the value of 18 F-FDG PET/CT in the diagnosis of 41 indeterminate adrenal masses (in 37 patients). They showed that the use of a T mx :L mx uptake ratio was more accurate than VA in the distinction between benign and malignant tumors, with an optimal threshold value of 1.8 (10) . The main limitation of the study was related to the low proportion of ACC. The interest of using a semiquantitative scale has also been shown by other studies (11, 12 The current study confirms that T mx :L mx or T mx :L me uptake ratios are valid predictors of malignancy. When using a cutoff value of 1.5 for differentiating benign from malignant tumors, the overall sensitivity and specificity of the T mx :L mx ratios were 86.7% and 86.1%, respectively. However, clinicians should be aware that ACC and retroperitoneal sarcomas that can mimic large adrenal tumors can exhibit low to moderate uptake values. Although VA and uptake ratios had similar sensitivities, the ratios provided a better specificity.
In our study, the median size of tumors was relatively large at 42.1 mm for benign tumors and 59.3 mm for Figure 1 . ROC curves from the (T mx :L mx ) ratio for the diagnosis of malignancy (N = 87). Criterion, optimal threshold value; Se, sensitivity; Sp, specificity. malignant tumors. This is due to the inclusion criteria and also probably because most patients were referred by endocrine surgeons. Because tumor size represents a useful predictor of malignancy, a model that takes into account tumor size and T mx :L mx uptake ratio would be of particular interest for personalized stratification risk of malignancy.
We acknowledge several limitations in our study: small number of patients leading to an impossibility to split the data set for formulating the logistic regression model, multiple centers with different PET cameras, absence of standardization of PET/CT acquisitions and reconstruction algorithms, and absence of calibration of cameras between centers. Furthermore, the results of PPV and NPV are described, but these parameters depend on disease prevalence and the prevalence of ACC should be considered as relatively high in the current study due to the inclusion criteria. Although the risk of ACC is unlikely in adrenal masses that remained stable or had minimal increase in size during 1 year, a 1-year follow-up visit should be considered as relatively short for the ultimate classification of adrenocortical tumors via imaging. Finally, for ethical reasons, patients having adenomas with Weiss scores of 1 and 2 were not followed by adrenal imaging. Although there is a variable interobserver reproducibility in assessing the Weiss score, the fact that tumors were classified by trained pathologists (14) and all patients were alive after 4.5 years makes the risk of malignancy very unlikely. Despite these limitations, this is the largest study of its kind with a prospective design, and optimal T mx :L mx uptake ratio values have been determined in real-life situations.
In conclusion, incidental adrenal masses are now common and can be difficult to characterize in the case of unenhanced $10 HU and/or tumor heterogeneity. The management of indeterminate adrenal tumors is not yet fully validated despite the recent European guidelines (9) . Within the limitations of this study, the use of qualitative and quantitative assessment of 18 F-FDG uptake (T mx :L mx ) provides additional information to washout adrenal CT in the evaluation of adrenal masses. We would, therefore, recommend that patients with large and/or indeterminate adrenal masses be evaluated with 18 F-FDG PET/CT.
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